STAAR Surgical sees FY18 revenue about $124M, consensus $123.27M

“Global demand for our ICL product lines continued to expand during the fourth quarter, and all signs currently point to this momentum continuing into 2019,” said Caren Mason, President and CEO. “China led the way with ICL unit growth of approximately 99% in the fourth quarter, sequentially consistent with the growth we reported for the third quarter of 2018. As we planned, STAAR Surgical’s business in the U.S. also returned to growth. We began the staged rollout of the Toric ICL in the U.S. to certified surgeons in late October leading to approximately 16% growth for the ICL in the U.S., compared to the prior year period, in the world’s second largest refractive surgery market.”
https://thefly.com/landingPageNews.php?id=2844711